Shenzhen Salubris Pharmaceuticals Co., Ltd.
SZSE:002294 Rapporto sulle azioni
Cap. di mercato: CN¥35.7b
Shenzhen Salubris Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 6/6 Shenzhen Salubris Pharmaceuticals ha un patrimonio netto totale di CN¥8.6B e un debito totale di CN¥60.0M, che porta il suo rapporto debito/patrimonio netto a 0.7%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥10.2B e CN¥1.6B. L'EBIT di Shenzhen Salubris Pharmaceuticals è CN¥594.0M rendendo il suo rapporto di copertura degli interessi -10. Ha liquidità e investimenti a breve termine pari a CN¥1.9B.
Informazioni chiave
0.7%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi -10x Contanti CN¥1.91b Patrimonio netto CN¥8.64b Totale passività CN¥1.59b Totale attività CN¥10.23b
Aggiornamenti recenti sulla salute finanziaria
Mostra tutti gli aggiornamenti
These 4 Measures Indicate That Shenzhen Salubris Pharmaceuticals (SZSE:002294) Is Using Debt Safely Nov 11
Third quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.13 in 3Q 2023) Oct 22
Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024 Sep 30
We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings Sep 02
Price target increased by 7.2% to CN¥37.50 Aug 30
Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 2Q 2023) Aug 27
What Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) P/E Is Not Telling You Aug 23
Are Investors Undervaluing Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) By 21%? Aug 02
Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024 Jun 29
Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Not Quite Adding Up May 22
First quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.19 in 1Q 2023) Apr 24
A Look At The Fair Value Of Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) Apr 17
Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024 Mar 30
Shenzhen Salubris Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 22, 2024 Mar 26
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 26
Is Shenzhen Salubris Pharmaceuticals (SZSE:002294) A Risky Investment? Feb 28
Investor sentiment improves as stock rises 17% Feb 07
Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024 Dec 29
Consensus EPS estimates fall by 11% Nov 16
Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.18 in 3Q 2022) Nov 01
Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.095 in 2Q 2022) Aug 25
Upcoming dividend of CN¥0.50 per share at 1.4% yield May 02
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 30
Price target increased to CN¥30.65 Jan 06
Consensus forecasts updated Oct 31
Price target increased to CN¥25.35 Oct 25
Investor sentiment improved over the past week Oct 14
Second quarter 2022 earnings released: EPS: CN¥0.095 (vs CN¥0.073 in 2Q 2021) Aug 11
Price target decreased to CN¥20.00 Jun 24
Consensus revenue estimates increase by 10% Apr 27
High number of new directors Apr 27
Shenzhen Salubris Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on April 27, 2022 Apr 21
Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2021 Apr 20
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 31
Shenzhen Salubris Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 18, 2022 Mar 31
Shenzhen Salubris Pharmaceuticals Co., Ltd. Proposes Dividend for 2021 Mar 30
Consensus EPS estimates fall by 13% Mar 18
Price target decreased to CN¥25.00 Mar 17
Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.07 in 3Q 2020) Oct 26
Price target decreased to CN¥22.60 Sep 10
Second quarter 2021 earnings released: EPS CN¥0.073 (vs CN¥0.047 in 2Q 2020) Aug 24
ROSY METRO LIMITED acquired a 13.78% stake in M.A. Med Alliance S.A from Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) for $45 million. Jun 15
First quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.14 in 1Q 2020) Apr 20
Consensus forecasts updated Apr 17
Consensus forecasts updated Apr 09
Consensus revenue estimates fall to CN¥3.35b Apr 05
Full year 2020 earnings released: EPS CN¥0.06 (vs CN¥0.68 in FY 2019) Mar 30
New 90-day high: CN¥38.86 Feb 05
New 90-day high: CN¥32.23 Jan 21
Price target raised to CN¥22.60 Jan 13
New 90-day low: CN¥27.10 Dec 09
Analysts lower EPS estimates to CN¥0.45 Dec 09
New 90-day low: CN¥29.41 Nov 06
Analysts increase EPS estimates to CN¥0.62 Oct 31
Third quarter earnings released Oct 23
Annual earnings released: Earnings miss expectations Oct 23
New 90-day low: CN¥31.70 Oct 19
Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020 Oct 17
Shenzhen Salubris Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 2 billion in funding Oct 02
Analysts update estimates Sep 02
New 90-day high - CN¥41.20 Sep 02
Price target raised to CN¥17.84 Aug 27
Earnings released Aug 27
Shenzhen Salubris Pharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020 Aug 11
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) completed the acquisition of remaining 15.7% stake in Salubris (Suzhou) Pharmaceutical Co., Ltd. from a group of shareholders. Jul 31
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( CN¥3.8B ) di 002294 superano le sue passività a breve termine ( CN¥1.0B ).
Passività a lungo termine: Le attività a breve termine di 002294 ( CN¥3.8B ) superano le sue passività a lungo termine ( CN¥576.9M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: 002294 ha più liquidità del suo debito totale.
Riduzione del debito: Il rapporto debito/patrimonio netto di 002294 si è ridotto da 5.4% a 0.7% negli ultimi 5 anni.
Copertura del debito: Il debito di 002294 è ben coperto dal flusso di cassa operativo ( 1930.7% ).
Copertura degli interessi: 002294 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
